Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Heres a question for the board, if ALL OF YOU ARE “LONG CVSI” & Holding Your Shares, Whose 1/2 400,000+ shares were sold into the market in the opening 45 minutes This A.M?
Heres a “Key Statistic” CVSI Opens Down IN THE RED struggling to stay above that key $5.00 support level while Michael Mona Jr. now free of Insider restrictions continues to bleed shares into the float. I know, I know “Uplist coming” Tic Toc, Tic Toc Day 196 and counting.
CVSI is like an etiolated Hemp Plant. Slowly dying. As soon as serial fraudster Michael Mona Jr. cashed out the 22 million shares he’s bleeding into the float it will finally die. As for Mona being a serial convicted fraudster here are the citations from public records proving it
(1) In 2011, Mona was on trial in California for fraud. After the trial, the court said he “intentionally defrauded” the plaintiff by “misrepresent[ing] material facts and conceal[ing] other material facts.” Mona was ordered to pay $16,886,132.16 for damages caused by his fraud. The judgment grew to $17,846,651.92 prior to Mona deciding he wouldn’t pay one penny and he filed Bankruptcy.
(Source: Far West Indus. v. Mona, et al., California Superior Court, Riverside County, No. RIC495966.)"
(2) https://www.sec.gov/litigation/admin/2018/34-83391.pdf
NBC 6 Miami will televise a report entitled Patients Are Being Duped By CBD’s Tomorrow Leading Their 6:00 P.M. Broadcast
The actual television report will go far deeper then the website introduction, I’d advise all CBD Proponents whether you’re a CBD product user or a CBD Company stock holder to tune in. Numerous CBD Companies as well as whether CBD is effacious in helping any disease will be discussed. One topic will be the fact that CBD’s have been studied and studied and there is yet to be any scientific evidence it’s medicinal for anything beyond Dravets Syndrome and Lennox-Gastaut syndrome. Worldwide there are currently 9,000 patients diagnosed with both afflictions combined and they already have approval for treatment with Epidolex, a new drug that has undergone the rigorous Phase I, II and III clinical studies and trials in order to be both FDA and Worldwide approved.
This unfortunately leaves CVSI to plow its way in the dregs of the pseuscientific neutaceutical industry in the sewer of the OTC.
CVSI’s product are it’s OTC Shares not any medicinal value at all. None
All on the backs of these poor, horribly ill 9,000 children.
https://ghr.nlm.nih.gov/condition/lennox-gastaut-syndrome
https://www.acfp.ca/wp-content/uploads/tools-for-practice/1510681044_tfp199mmandpainfv.pdf
It takes the likes of a convicted fraudster who shirks his $17,000,000.00 judgment by filing Bankruptcy. CVSI’s founder Michael Mona Jr. was on trial for fraud In 2011, Mona was on trial in California. After the trial, the court said he “intentionally defrauded” the plaintiff by “misrepresent[ing] material facts and conceal[ing] other material facts.” Mona was ordered to pay $16,886,132.16 for damages caused by his fraud. The Judgment reached the whopping total of $17,841,652.92 - As opposed to paying one penny Michael Mona Jr. filed Bankruptcy.
(Source: Far West Indus. v. Mona, et al., California Superior Court, Riverside County, No. RIC495966.)"
Thereafter Mona was forced out of his own or any public company for....wait for it.....F R A U D yet again. It’s fair to say at this point Michael Mona Jr. is a serial Fraudster. Coupled with a new President that replaces him who never saw a Tax bill he owed that he liked so instead of paying them he piles up Federal and State Tax Liens.
All of these Tax Liens, Judgments, Fraud Convictions, etc are easily found performing some proper due diligence in Public Records.
Do you think NASDAQ wants these type Executives running the Companies listed on their exchange?
CVSI a company run by known Fraudsters and Tax Cheats, but an uplist is coming Tic Toc, Tic Toc
No, it’s not.
How sad.
NBC REPORTS PATIENTS ARE BEING DUPED OVER CBD
CVSI is included in the comprehensive television reporting airing tomorrow.
https://www.nbcmiami.com/investigations/505335101.html
No, CVSI is not “strong” and Zack’s does not change ratings “everyday.”
Hold not buy is what Zack’s has CVSI rated
Do you consider that a good rating predicting growth in the future?
They don’t mention any any “uplist,”
Zack’s also does not recommend buying the stock.
Don’t be surprised if that Hold recommendation changes.
Not sure what you’re asking, is it how can you get a tour of the Teco or LSU Facility?
What you did was Incorrect as you either misunderstand or have never read a TD Statement. Column 1 is the date, column 2 is the amount of shares purchased column 3 is the share cost. If you do your addition properly you will see I purchased 114,544 shares of CVSI for a total of right at $47,000.00 for a per share cost of about $.41
As for my day trading you can see it was just under a million dollars purchased (and sold) the same day or within 24-48 hours.
This is all I use this TD Account for, day trading CVSI stock after I sold the initial position for about $400,000.00
My only other stock holdings are as a partner in IBEX Venture Capital and Hedge Fund or in the case of OTC stocks via PRIVATE PLACEMENT
Yes, 17 of the 22 Canabbis tickers I track were up yesterday while CVSI was down, in the RED and still no fantasy “uplist” 192 days and counting.Tic Toc, Tic Toc,
Now it’s irrelevant as Canopy has entered the space investing 150 million dollars in just one state, NY., This one minor investment for Canopy is equivalent to 1/3 of the entire CVSI market cap.
The big boys from the big boards have hit the sector with enough money being invested from NASDAQ and NYSE Companies to crush CVSI and the stinky pinky OTC Markets non stock exchange from whence they came.
Perhaps that’s why Michael Mona Jr. finally retired so he can bleed the 20+ million shares he’s now begun to sell diluting all the retail stockholders.
I sold my 115,000 shares I bought for $.40 as you see below for a $400,,000.00 pre tax profit
Just another easy spotting of an OTC Pump and Dump Play. I do it all the time.
No it’s not and certainly not looking good for the mining “business,” or for this ticker. Funny how that theme clearly carries across very specific boards.
NYSE Firm Pyxus International (NYSE: PYX) enters Hemp / CBD Market via their subsidiary Criticality and their CBD Line Of products, Korent.
Upon the announcement today PYX Shares moved upwards 30% on the BIG BOARD opening at $13.00 and at one point reaching $17.98 before closing at $16.75 PYX had volume of 3,504,994 shares. Prior 10 day average share sales were 1 million per day making today’s announcement and subsequent action a record amount of dollars changing hands over ANY Hemp or CBD Company. A whopping amount of 60 Million Dollars traded and That’s just on the FIRST DAY. Triple the largest amount of Dollars CVSI has ever traded on one day in over 6 months and this was the first day. With a low float of only 9 million shares, this NYSE Multi State Agricultural Conglomerate Are sure to quickly become one of the U.S. Market Leaders in this sector joining Canopy and CWeb which trades in Canada on the CSE,Canadian Securities Exchange Canada’s equivalent of the U.S. Big Board .
https://www.prnewswire.com/news-releases/criticality-expands-product-portfolio-with-launch-of-korent-cbd-e-liquids-300787253.html
As to who the prior market leader was / is the following chart should help. Everyone in the sector has been on a positive run in the past week, some more than others. Only a Contrarian or Apoplectic 17 year old would have missed out on making bank trading in this sector this past week.
Current accepted market leader CWeb which unfortunately trades in the US on the lesser OTC non stock exchange had a roaring week far exceeding its O/S bloated competitor still awaiting an “uplist” (tic toc) after 6+ months, CVSI. Due to CVSI’s poor past history of SEC Fraud Fines, Suspensions, Actions, Lawsuits, bad debts leading to an 18 Million Dollar Bankruptcy by their founder, one week into retirement but still CVSI’s largest shareholder by far, along with SEC Fraud Fines and Actions against their former Auditor Anton and Chia combined with current President Joseph Dowling’s past Federal and State Tax Liens make it highly unlikely if not impossible CVSI will ever reach a real Stock Exchange They’ll be left to muddle along in the dregs of the OTC Markets formerly known as The Pink Sheets made infamous by such firms as Stratton Oakmon, it’s jailed founder Jordan Belfort and Films depicting the manipulation and fraud such as Wolf Of Wall Street and another, Boiler Room. The reason the OTC Markets continues with this reputation is it’s not a real Stock Exchange but a is a decentralized market where non-listed securities such as CVSI are traded by market participants. There is no centralized place to make the trade. Instead, the market consists of all the participants trading amongst themselves as deals are done directly between broker/dealers who make two-way prices to each other in the stocks that they are trading in allowing for regular manipulation by said “market makers.”
Their hopes of being the first U.S. based Cannabis or Hemp firm to be traded on a REAL Stock Exchange were crushed today by NYSE Firm Pyxus International (NYSE: PYX), who traded a whopping $60,000,000.00 of stock after simply announcing the Agricultural Conglomerate was entering the space thereby making CVSI’s “uplist” attempt (tic toc) moot.
In all likelihood CVSI will never trade on a real Stock Exchange due to the myriad of SEC Fines, Enforcement Actions, lawsuits, bad debts, bankruptcies, Fedaeral and State Tax Liens by virtually everyone who has had anything to do with this “company.”
Meanwhile comparing the prior Market Leader CWeb by chart over this recent run to CVSI and adding the true World Cannabis Leader, Canopy who also announced this week a 150 Million Dollar Initial foray into this currently hot Hemp space to the chart for clarity’s sake makes it clear CVSI is by far the laggard and now with competition from a NYSE Firm AND Canopy they’re certain to lag even quicker and further.
Perhaps these events are what led Mr. Michael Mona Jr. to step down in order to sell his 20 million plus shares in CVSI as has been the rumors swirling amongst the cesspool of the OTC since his making the announcement last week. Unfortunately we won’t know until far down the road, too late for retail investors who will find their positions highly diluted and their former sales taken over by the big boys. The chart shows CVSI lagging already.
Caveat Emptor.
Let’s look at the chart for even further proof where it can be seen just today how far CVSI is lagging and this doesn’t take into account the entry of NYSE Firm Pyxus International (NYSE: PYX) entrving the sector.
If you don’t know who was selling the largest amount of CVSI stock sold yesterday allow me to enlighten you .
Michael Mona Jr. and proxies.
From OTC Markets;
The Transfer Agent Verified Shares Program provides reliable share data to investors of OTCQX, OTCQB and Pink securities by allowing participating transfer agents to submit verified shares outstanding information on a regular basis for their clients directly to OTC Markets Group.
Share data provided by participating transfer agents is displayed alongside a “Transfer Agent Verified” logo on www.otcmarkets.com, indicating that the information is reliable and trustworthy. CVSI and their T.A. refuses to participate in The Transfer Agent Verified Shares Program provideing reliable share data to investors.
This data is also disseminated through OTC Markets Group’s data products along with other security-related information to interested parties that rely on our data as the source for verified information on OTC securities.
Participating Transfer Agents:
Action Stock Transfer
American Registrar & Transfer Co.
AST - American Stock Transfer & Trust Company
Broadridge Financial Solutions, Inc.
Capital Transfer Agency, Inc.
ClearTrust, LLC
Colonial Stock Transfer Co. Inc.
Computershare US
Continental Stock Transfer & Trust Company
Corporate Stock Transfer
Direct Transfer LLC
Empire Stock Transfer
EQ Shareowner Services
Equity Stock Transfer
First American Stock Transfer
Globex Transfer, LLC
Heritage U.S. Transfer Corp.
Island Stock Transfer
Madison Stock Transfer Inc.
Manhattan Transfer Registrar Co.
Mountain Share Transfer
National Issuer Services, Inc
Nevada Agency and Transfer Company
New Horizon Transfer Inc.
Olde Monmouth Stock Transfer
OTR, Inc.
Pacific Stock Transfer
Philadelphia Stock Transfer, Inc.
Quicksilver Stock Transfer, LLC
Standard Registrar & Transfer Co., Inc.
Securities Transfer Corporation
Signature Stock Transfer, Inc.
Transfer Online, Inc.
VStock Transfer
West Coast Stock Transfer, Inc.
Worldwide Stock Transfer, LLC
Effective January 1, 2019, U.S. OTCQX and OTCQB companies will be required to provide verified share data through a transfer agent who participates in the Transfer Agent Verified Shares Program. OTC Markets Group will also use this data to confirm compliance with OTCQX and OTCQB market rules.
Unfortunately CVSI chooses to hide their O/S by using Interwest Transfer Company
1981 Murray Holladay Road
Suite 100
Salt Lake City, UT 84117
T: 801-272-9294
Why would CVSI, this “amazing, incredible, market leading company with such clean hands” chose a T.A. who refuses to be transparent and work within The Transfer Agent Verified Shares Program thereby providing reliable share data to investors?
Because they will never reveal CVSI’s O/S instead referring you to the last Q.
Why?
Because Michael Mona Jr. who has formally retired from every possible position currently making him ”just an investor”” be allowed to sell whatever he chooses. The difference is Mona Jr. holds a far greater position and his sales are bloating the current O/S’s giving him a period where no one but his son, Dowling and the rest of his former hand picked C-Suite employees know the real O/S. Wait until the May Q. There will still be no “uplist” (tic toc) and the O/S will be in the 125 to 130 million range diluting current investors 30% to 40% from here. This will continue until the CVSI S/P crashes like The Hindenburg. Guaranteed. Don’t say you weren’t warned, over and over and over again.
Mona only has to report any sales over 4.99% of the current O/S’s which retail investors will never know in a timely manner due to Interwest Transfer Co’s never revealing the actual current O/S’s. Don’t believe me? Call them up and ask, They’ll refer you to the last Q. Guaranteed. I’ve been an insider in a number of OTC Tickers. Interwest is just one of a handful of T.A’s we used to hide the O/S count.
Those are the facts believe them or not.
CVSI “investors” are in for a huge surprise with the May Q. You’ll begin to see the rise in O/S’s come the February Q. Not only was that report by Benzinga of lower sales correct, it was just leaked by accident. The O/S will be bloated near the 120 million mark on the May Q further diluting their positions. I remember this similar cult stock like moves with FITX. People going “all in” and on an OTC Stock as well. It is sad, truly sad. But in 6 months with still no “uplist” and diluted 30% to 40% from here his thing will crash like like The Hindenburg. Guaranteed.
Long ago Interwest used to be a Broker / Dealer as you can see below
What happened? Have a look;
License permanently revoked.
GLTA, you’re going to need it.
Interesting that you use that particular soliloquy from that particular author, Shakespeare’s, particular play, Hamlet as analogous to your situation with CVSI. Unless done intentionally you’ve misunderstood and therefore misquoted the metaphor within.
Hamlet is based around the life of a Danish nobleman and the struggles he encounters in his life, but most importantly it’s about revenge of someone he loves most dearly. A proper metaphorical analyzation of this monologue he has in the middle of the play in the palace he is staying in you first must understand the soliloquy like the play is about the struggle between life and death. Therefore to opine a proper metaphorical analysis one would first have to understand the meaning of first the entire text and then the soliloquy itself.
Shakespeare’s quote from the play Hamlet, “To be, or not to be? That is the question—Whether ’tis nobler in the mind to suffer The slings and arrows of outrageous fortune, Or to take arms against a sea of troubles, And, by opposing, end them?” Refers to the idea of whether is it better to live or to die. The topic of suicide was frowned and shamed upon this point in time but it was a popular theme in English literature since the idea was very prevalent in the minds of the common public at the time. The conclusion that Shakespeare himself didn’t mind the thought or the act of suicide. He talks more about how society brings misfortune more than it does fortune and that it would be okay to end it since it was indeed very frustrating and unfair. This point can be furthered in the second part of the lines.
“To die, to sleep—No more—and by a sleep to say we end the heartache and the thousand natural shocks that flesh is heir to—’tis a consummation devoutly to be wished! To die, to sleep.” My assumption about how Shakespeare views death through this play is sleep. He views death as a constant sleep in which you can never awaken from. I believe that the concept of death as a long slumber became popular through the Hamlet play. Shakespeare was very popular at the time this play was shown and passed down through out the years. He also continues the concept of suicide and how it could be an alternative to dealing with all the hardships life has to offer.
“To sleep, perchance to dream—ay, there’s the rub, for in that sleep of death what dreams may come when we have shuffled off this mortal coil, must give us pause. There’s the respect that makes calamity of so long life.” This portion of the famous Hamlet monologue is just about the concept of committing suicide or the thought of that action. But what is most fascinating about it the quote is the concept of dreaming if you’re dead. The logic of death according Shakespeare through this play is that death is just a long sleep. With sleep comes dreaming, you might know what you’re going to dream since you witness sounds, images and colors, but you can’t know what you will dream when none of those exist. This really puts a second thought in mind about suicide and is a very philosophical way of looking at the situation, what happens after death?
Perhaps there are those so troubled by the lack of any “uplist” after almost seven months of waiting since the CVSI application to chose this passage as a metaphor. Fair enough.
Perhaps there are those so troubled by Mona III’s remaining to do Mona Jr’s choices by proxy thereby holding back any chance of an “uplist” of CVSI to NASDAQ chose this Assange as a metaphor. Fair enough.
Perhaps there are those concerned by Mr. Dowling’s history of a $100,000.00 Federal Tax Lien easily found in public records as seen below to chose this passage as a metaphor for the CVSI to date non “uplist,”
Fair Enough.
Perhaps there are those who are concerned with Mr. Dowling’s past State Tax Liens amongst other unpaid past debts easily found in public records as seen below to chose this passage as a metaphor for CVSI’s failure to “uplis”t after a seven month wait. Fair enough.
I would simply urge no one in their anxiety or impatience of CVSI’s inability to date to “uplist” to chose Shakespeare’s true meaning of this passage to follow through on it. No, No, No, No.
No OTC Penny Stock’s inability to uplist to a real stock exchange is worth such a terrible and drastic choice.
With that as would the bard, I bid you adieu.
Non seulement pour l'instant ou pour aujourd'hui, mais pour toujours ou jusqu'à ce qu'il y ait une liste jusqu'à NASDAQ ou plus probable m. Mona Jr. et m. Mona III gonfle les actions en circulation assez pour apporter cette tour de Siloam s'écraser d'où il est venu.
Translation as required by iHub TOS
Not only for now or for today but forever or until such time as there is an up list to NASDAQ or more likely Mr. Mona Jr. and Mr. Mona III bloats the outstanding shares enough to bring this Tower of Siloam crashing back from whence it came.
https://edzardernst.com/2017/02/upper-neck-manipulations-by-chiropractors-regularly-cause-serious-harm-why-is-it-still-used/
Wow, first time I stopped in here in a long while. There are clearly still people following and buying this POS?
GLTA, you’re going to need it.
It’s interesting that you find an OTC ticker such as CVSI a stock that is recession or bear market proof considering Pink Sheet Stocks now known as OTC Market stocks do not trade on a stock exchange but through the easily manipulated, market maker OTC middleman as well as over 80% highly promoted.
Historically these stocks underperform the exchange traded stocks regularly and even worse during bear markets or reccessionary periods. More on that below at the bottom of the post.
Typically during bear markets and / or recessions one finds a clear pattern in the best place to invest your funds. Besides the obvious AAA rated, low return (but positive return T-Bills and T Bonds) one should note and be aware of precious metals such as Gold.
Other obvious potential investments that have shown over time to be a “safe haven” in these periods include
(1) Costco (NASDAQ:COST) offers much to consumers during hard economic times. With the need to save money, people will eat in more. They will often buy in bulk and will still prefer high-quality goods. All of these factors work in Costco’s favor.
Moreover, while other retailers have struggled, Costco’s growth continues. Same-store sales have increased by almost 10% during the first half of 2018. However, this number matters little to the bottom line. Due to its pricing, nearly all of Costco’s profit comes from its memberships. Membership renewal rates have held at around 90% despite last year’s membership price increase.
Further, with new locations opening, and expansion into China starting in 2019, membership increases will continue. For this and other reasons, analysts predict net income average growth of almost 11.9% per year for the next five years.
In 2017, the sentiment that Amazon (NASDAQ:AMZN) would take over retail hit Costco and other retailers hard. However, over the last 12 months, the stock has seen steady growth. It now trades near all-time highs. With a forward price-earnings (P/E) ratio of around 28, the stock could appear a little pricey at these levels. Still, if a downturn causes a significant pullback, investors looking for recession-proof stocks should look at COST stock.
(2) Disney (NYSE:DIS) With millions facing unemployment or underemployment during downturns, they find themselves with more free time. This creates an opportunity for Disney (NYSE:DIS) to serve as one of the downturn stocks as they provide low-cost entertainment.
Many regard its content library as the best available. This coincides well with the coming launch of Disney’s streaming service. Disney has voiced its intention to offer a lower price than its peer Netflix (NASDAQ:NFLX). While many customers will get both services, those focused on access to the best content library at the lowest price will choose Disney.
This along with ESPN, Marvel, Lucasfilm, the theme parks and Disney’s other ventures continue to drive Disney’s profits higher. Analysts predict an average profit growth rate of 11.5% per year over the next five years. Despite high growth, the stock has struggled. It still trades slightly below its 2015 high of just over $120 per share. Many sold DIS as cable revenues started to fall.
Still, because of Disney’s switch to streaming, this creates opportunity. The forward P/E for DIS stock stands at about 14.8. This represents a very low multiple for a stock seeing double-digit profit growth in most years. With the affordable entertainment Disney will offer, the profit growth for DIS stock should remain robust regardless of how well the economy performs.
(3) Dollar Tree (NASDAQ:DLTR) Of all recession-proof stocks, perhaps none define the category better than Dollar Tree (NASDAQ:DLTR). As an extreme discounter, the store holds a continuous appeal to lower-income consumers and for those who want to keep spending to a minimum. During a downturn, this draw also attracts those who would regularly shop at higher-end stores during better times.
However, even during these better times, DLTR stock has enjoyed average growth at about 16% per year over the last five years. Analysts believe growth will still hold at about 13.4% per year on average for the next five years. This growth will help it to compete with peers such as Dollar General (NYSE:DG) and Big Lots (NYSE:BIG).
Now could be a great time to buy DLTR stock, whether a downturn comes tomorrow or two years from now. Dollar Tree stock has fallen over 25% from its January, 2018 high. This gives the stock a forward P/E of around 14. Hence, both a downturn and its predicted growth will serve as catalysts to push the stock back to its high and perhaps beyond.
The company operates over 14,800 stores in 48 states and five Canadian provinces. At a market cap of only $20 billion, Dollar Tree stands as a large company that will enjoy steady growth in the years ahead regardless of how the overall economy performs.
(3) This should be interesting to the members of this board. NYSE:TAP) and Constellation (NYSE:STZ) Molson Coors (NYSE:TAP) and its peers have faced challenges as consumers increasingly turn to craft beers. Others have turned to wine and spirits, or away from alcohol altogether.
During the last recession, consumption of mainstream beers fell as consumers turned to craft beers. The company saw the writing on the wall. They set out to acquire multiple craft breweries in various regions of the country. Some, such as Blue Moon and Leinenkugel, sell nationally. Other brands, such as Hop Valley or Revolver, come closer to the “microbrewery” concept, selling only in select regions of the country. This leaves Molson Coors with a wide variety of products to sell to both the low-end consumers and those who want to enjoy a “luxury” craft brew as they drown their sorrows during a downturn.
The trend toward cannabis legalization could also benefit TAP stock. Spirits producer Constellation (NYSE:STZ) bought a stake in Canadian weed company Canopy Growth (NYSE:CGC) last year. Many believe TAP is eyeing a similar stake in a cannabis company. If true, this could also bolster revenue and earnings, which would help TAP to prosper as one of the better downturn stocks.
The stock trades at a forward P/E of 13. TAP stock saw minimal profit growth over the previous five years. Still, analysts predict profit growth will come in at almost 7.7% per year on average for the next five years. A move into cannabis would likely increase that estimate. Whatever happens with the economy, investors will have what they need to relieve the pain available on TAP.
(4) Teladoc (NYSE:TDOC) Healthcare equities tend to function well as recession-proof stocks. Even in a booming economy, the rising cost of healthcare has served as a source of worry for many Americans. However, Teladoc (NYSE:TDOC) appears ready to cut the cost of doctor visits. For $40, patients can receive a virtual visit from a doctor at any time via their PC or smartphone. This allows for treatment solutions at a lower cost without the wait.
(5) T-Mobile (NASDAQ:TMUS) T-Mobile (NASDAQ:TMUS) and its peers are spending tens of billions of dollars over the next few years to upgrade to 5G technology. 5G promises to revolutionize the wireless industry and perhaps the tech industry as a whole. Tests indicate it will bring speeds between 10 and 60 times faster than 4G. This will improve wireless connectivity and bring the world apps and functions not possible in the 4G realm. One such application is connectivity to Internet of Things (IoT) devices. Others have yet to be imagined.
However, this places pressure upon T-Mobile, as well as AT&T (NYSE:T) and Verizon (NYSE:VZ), to complete the 5G upgrade to stay relevant in the wireless business. Thus, the move to 5G will continue regardless of how the economy performs. Moreover, people must communicate in good times and in bad. This need will help T-Mobile and its peers as downturn stocks.
The high costs of the upgrade have drawn away stock investors. Hence, the forward P/E stands at under 19. However, analysts predict profits will grow by over 17% this year and 22% next year. Moreover, the company will begin reaping the benefits soon. T-Mobile expects to launch 5G in 30 markets by early next year.
Also, assuming they can complete the long-desired merger with Sprint (NYSE:S), T-Mobile will see a broader customer base and only two direct competitors in the U.S. With or without Sprint, and with or without a booming economy, T-Mobile and TMUS stock will move ahead at full speed.
Analysts estimate over 400 million doctor visits per year, about one-third of the total, could take place on such a platform. Teladoc holds well over 50% of the market share in telehealth. It expects to conduct between 1.9 million and 2 million appointments this year.
The growth potential remains enormous regardless of how the economy performs. However, unemployed workers often drop health insurance during downturns. Thus, TDOC could provide quick, life-saving treatments to those who might not otherwise be able to afford a doctor.
The company has invested heavily in improving diagnostics and taking this service outside the U.S. As a result, it has spent heavily, and profitability will not come in the foreseeable future. Also, with TDOC trading at more than 14 times sales, it has become an expensive stock.
However, revenue growth has approximately doubled every year since 2013. Analysts forecasts revenues to rise by over 70% this year and over 35% in 2019. With a majority of the market share, a $4.5 billion market cap and more than 99% of the potential market left to be addressed, TDOC stock should rise regardless of what happens to the economy.
Lastly, there are far riskier ETC traded Funds that leverage the potential recession or bear market. Some of these include but are not limited to
TQQQ - The Fund seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Index. (300% of the NASDAQ 100) Expenses .92%
SQQQ - ProShares UltraPro Short QQQ (the “Fund”) seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the return of the Nasdaq-100 Index® (the “Index”) for a single day, not for any other period. (300% of the NASDAQ 100) Expenses .95%
SPXS - The Direxion Daily S&P 500® Bear 3X Shares (the “Fund”) seeks daily inverse leveraged investment results. Fee’s .75%
SPXU - The Fund seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Index (300% of the S&P 500) Expenses .91%
These are all highly leveraged and should be bought only if the investor is convinced the day of investment will be a down day. However strictly for a point of information, pre-market trading on all three (3) mentioned ETF’s today are above 1% indicating a highly potential down day with SPXU trading right now 6:13 A.M at + 1.5%
While I believe there was a mention of CVSI being a healthcare stock, CVSI It is NOT a healthcare stock It is a Nutraceutical ingredient as well as vitamin or supplement ingredient stock and must ther fore contain the following FDA Disclaimer:
This content is for informational purposes only and is not meant to replace the guidance of your licensed healthcare practitioner. Statements on this website have not been evaluated by the Food and Drug Administration. Information and products are meant for general use only and are not intended to diagnose, cure, treat, or prevent any disease or provide medical advice
Discussion Of Performance Of OTC Stoks
Division of Economic and Risk Analysis 2
Citations: Aggarwal and Wu, 2006; Nelson et al., 2013; Massoud et al., 2016). Although one potential attraction of investing in OTC stocks is the chance to invest early in a small company that may eventually grow into a larger one, empirical evidence shows that OTC stocks rarely transition (“graduate”) to an exchange (Brüggemann et al., 2016). Despite the perilous properties of OTC stocks, the growing size of OTC Markets suggests that investors’ demand for these stocks has grown in recent periods. Academic literature posits two hypotheses to explain why individuals continue to invest in OTC stocks despite the tendency for poor investment outcomes. The first hypothesis is that OTC investors are simply gambling since OTC stocks have a lottery-like distribution of returns. The second hypothesis is that investors are poor at estimating return probabilities of OTC stocks because these companies tend to provide fewer disclosures. Most academic studies provide empirical evidence more consistent with the second hypothesis and conclude that OTC investors systematically misestimate return probabilities (Nofsinger and Varma, 2014; Eraker and Ready, 2015). However, little is known about the characteristics of OTC stock investors and their correlation with investment outcomes, especially around stock promotions and disclosure-related eligibility requirements.
To shed light on this issue, examining OTC investor stocks outcomes using a dataset of 1.8 million trades by more than 200,000 individual investors. Consistent with existing academic studies, I find that the median OTC investor experiences significantly negative investment returns. Investor outcomes worsen for OTC stocks that are promoted, and for companies with weaker disclosure-related eligibility requirements self-established by OTC Markets. Analysis of demographic information reveals that returns on OTC stocks are significantly worse (i.e., more negative) for elderly and retired investors, and those with lower levels of income and education.
This study contributes to our knowledge of OTC markets in several ways. First, I highlight an important trend in the OTC Markets towards a greater composition of companies in the tier with fewer self-established eligibility requirements pertaining to disclosure. Second, providing a broad review of recent academic studies that document the distinct properties of OTC stocks. Third, while many studies examine overall OTC stock returns with cross-sectional data, we know very little about individual OTC investor characteristics due in large part to data limitations. Thus, this study also contributes by extending our understanding of the OTC market through direct, transaction-level evidence using confidential trading information to reveal the correlation between OTC investor demographics and investment outcomes. The academic literature on transaction-level OTC investments is limited to a single study by Nofsinger and Varma (2014). This paper examines investor demographics using a sample of approximately 16,000 investors and 42,000 OTC trades at a single brokerage over 1991 to 1996. This covers a much more recent time period and includes a considerably larger OTC dataset of more than 200,000 investors and 1.8 million trades across a number of brokerages. To my knowledge, looking at OTC investor outcomes around stock promotions and OTC Markets’ self- established eligibility requirements related to disclosure using transaction-level data. The return properties of OTC stocks are distinct from stocks listed on national securities exchanges. Empirical evidence shows that OTC stock returns are typically negative, volatile, and highly skewed.
Investing in OTC stocks, on average, generates negative returns for investors (Luft et al., 2001; Ang et al., 2013; Nofsinger and Varma, 2014; Eraker and Ready, 2015; Jiang et al., 2015; Brüggemann et al., 2016). For example, Brüggemann et al. (2016) study a sample of over 10,000 OTC stocks from 2001 to 2010 and find average and median annual returns of –27% and –37%, respectively. Similarly, Eraker and Ready (2015) study a sample of approximately 6,800 OTC stocks between 2000 and 2008. The investors in their sample average a –24% annual return after accounting for transaction costs. Moreover, these OTC investors lost an aggregate of $180 billion over the sample period.
For many years, academic papers have identified stocks of smaller companies as being riskier investments than those of larger ones (e.g., Banz, 1981). Brüggemann et al. (2016) report that the majority of OTC stocks have a small market capitalization and that the median OTC stock is priced as a penny stock.19 Moreover, OTC stocks have greater liquidity risk than those trading on a national securities exchange. Thus, one natural question is whether the negative returns in OTC stocks might simply reflect the exposure of investors to larger amounts of risk. In other words, OTC stocks might generate a negative actual return but a positive risk-adjusted return.
Empirical evidence rejects this notion.
To answer this question, academic studies examine OTC stock returns after accounting for known risk factors, such as company size. These studies find that, in addition to negative actual returns, OTC stocks also exhibit negative risk-adjusted returns (Ang et al., 2013; Eraker and Ready, 2015; Brüggemann et al., 2016). Eraker and Ready (2015) show that a portfolio of OTC stocks underperforms a portfolio of exchange-listed stocks by about 2% percent per month including transaction costs. As noted above, Ang et al. (2013) find that even the most liquid OTC stocks still generate a negative risk-adjusted return.
The returns of OTC stocks are also significantly more volatile than exchange-listed stocks (Ang et al., 2013; Brüggemann et al., 2016). For example, Brüggemann et al. (2016) find the volatility of OTC stock returns is more than two times larger than the return volatility of a matched sample of Nasdaq-listed stocks.
Academic studies point to a lack of information produced by OTC companies as one determinant of negative and volatile OTC stock returns (Luft et al., 2001; Luft and Levine, 2004). Leuz et al. (2008) study a sample of just under 500 companies that stop reporting to the SEC (i.e., “go dark”), but continue to be quoted on the OTC markets. They find that the stock price of those companies experiences an abnormal decline of approximately 10% when the company announces the decision to suspend disclosures to the SEC.20 Litvak (2009) studies OTC stocks after OTC Markets introduced a classification of tiers on the basis of self-established eligibility requirements pertaining to company provided information and finds that the market reaction was significantly negative for companies assigned to the lower-disclosing categories.
Another possible determinant of negative OTC stock returns is short-sale constraints (Aggarwal and Wu, 2006; Ang et al., 2013; Eraker and Ready, 2015). In the presence of constraints on short selling, stock prices do not fully reflect the views of bearish investors and thus are less informative about the true market value (Miller, 1977). In equilibrium, this situation results in stock prices that are too high (Jarrow, 1980) and increases the risk of large declines in stock prices around bad news (Hong and Stein, 2003). Ang et al. (2013) and Eraker and Ready (2015) argue that the short-selling of OTC stocks is challenging for investors because of brokerage restrictions and difficulties in locating OTC shares to sell short. Ang et al. (2013) further suggest that negative risk-adjusted returns due to short-sale constraints should be stronger for stocks with a greater divergence in opinions between optimistic and pessimistic investors. Using a subset of OTC companies that do not disclose financial information, they find that stocks with a high divergence of opinions among investors have more negative risk-adjusted returns. Jain and Jain (2016) study short-selling activity in OTC stocks. They provide suggestive evidence that return patterns and short interest levels reflect manipulative behavior by OTC short sellers that is not informative.
The above references an opinion and is for information purposes only. It is not intended to be investment advice. Seek a duly licensed professional for investment advice.
Interesting article about CVSI CBD Oil in today’s Chiropractic Economics Magazine
This can be found at the following URL;
https://www.chiroeco.com/chiropractic-case-study-risk-vbs/
A New Scam
Look out for this group who brought you PHOT (sent to greys), then VAPE (lawsuits from convertible investors) unable to convert due to the bloated ONE BILLION O/S Count
The infamous Kyle Tracey, Jordan Scott and Joe Andrae’s Group now is preparing via Reverse Merger to bring you ”ReStalk”
http://www.restalk.org/#intro
Coming to an OTC P$D Ticker in order to sell shares to you soon.
They’ve also got backups in the CBD Sector on tap (CeBaDora)
https://www.cebadora.com
And if that weren’t enough they’ll sell you hip hop Cannabis Clothes ”Bro” under the name ZKittlez
https://www.zkittlez.com
All owned, operated and run by the GrowLife (PHOT) and VAPE Crew.
A recently received e-mail from Kyle Tracey was signed;
Kyle Tracey
F/ELD | ReStalk | ZKITTLEZ
Madrone | CeBaDora | HIVE
Notice he left the PHOT and VAPE names off. It’ll be more difficult to remove the GrowLife tattoo he had embalmed on his arm 2 weeks prior to the PHOT SEC halt. A company in which he held the title “Interim CEO” for two years.
Marty,
This leaves Joseph Dowling “formally” in charge of CVSI. I say “formally” as retired or not Mona Sr. is by far the largest shareholder of CVSI, his son Mona III remains at the company as Mona Jr’s proxy to continue to do his bidding. Lastly, Mr. Dowling doesn't have what the SEC, FINRA or NASDAQ calls “clean hands.” He appears to have problems in his past paying his bills leaving in his wake liens, judgments and unpaid creditors. These include both State and Federal Tax Liens. The Federal lien being just under $100,000.00 pre interest and fines. Not exactly what NASDAQ looks for in its exchanges CEO’s, Presidents, B.O.D members or any employee or insider of the company applying for membership . There are a myriad of other issues as well in the reason why no NASDAQ Uplist has yet occurred even after this six month wait. Attack if you like but this is simple due diligence all information gleaned from Public Records into just whom is running this company and their history.
A second State Tax Lien is listed in public records as well. You can tell these are two separate liens as they have different case numbers.
Also trades after hours bring CVSI back into yet again, the RED. It’s listed in this article today from Seeking Alpha under Losers;
https://seekingalpha.com/news/3424904-ibm-apha-cof-among-notable-hour-movers?app=1&dr=1#email_link
I’ve gotta run as in 3 hours Djokovic plays #8 seed K. Nishikori.
Good luck with that uplist.
Correct!
jefra1965 Saturday, 01/19/19 11:46:12 AM
Re: None 0
Post # of 41132
THIS IS NOT AN OFF-TOPIC POST
IT seems like CVSI HAS A SERIOUS CONGOLESE COMPETITOR
Let's do the math: That company claims to have 2 Million liters of CBD.
We have concluded it is MJ and NOT HEMP. No, YOU have concluded that. Both are actually being grown and extracted.
Let's say it is a good CBD MJ Strain containing 5% CBD per dry weight. Lets say? Sure. Let’s also say it was grown by Fred Flinstone on the moon. Both are equally valid. Invented without a citation
A good HEMP strain contains any where from 14 to 17 % CBD.
But this is NOT the case But is a conjunction. Although 10% of sentences on the Net begin with conjunctions, Starting virtually every sentence with a conjunction would, of course, make your writing thoroughly monotonous.
because it is MJ what they say they have - Nope, Invented without a citation
(NOT A SINGLE PICTURE of an MJ plot) So what, read the story. Every true written word doesn’t contain pictures so widdle boys can understand them. Those are called comic books. Invented without a citation
So here we go: So is a conjunction. Although 10% of sentences on the Net begin with conjunctions, Starting virtually every sentence with a conjunction would, of course, make your writing thoroughly monotonous.
THIS IS NOT AN OFF-TOPIC POST Why do you keep writing that? Are you trying to convince yourself?
I looked it up last nite (sic) You mean night, that’s the correct spellingand vegetable oils density range goes from from 0.88 to 0.94 so I will use 0.92.
because it is MJ what they say they have - Nope, Invented without a citation
2 Million liters of CBD weights around 1.84 Million Kilograms. Nope, Invented without a citation
And you need 36.8Million Kg of a 5% CBD strain MJ to get that kind of bulk of CBD. Nope, Invented without a citation as well as and being a conjunction
36.8 MILLION KG of MJ flying under the radar with NO PICTURES TAKEN in a few months operation. What's Canopy or Tilray (Or any LP) producing this days??? Or the top 5 LP combined???? b]Irrelevant, Invented without a citation
Has anybody seen NARCOS MEXICO on Netflix??? The series about the mexican marijuana cartel in the 80's where the DEA had to stand on the roof of their 4x4 trucks to see how big the ganja plantation was and the view got lost over the horizon.
Well I was expecting a picture like that fron INSTADOSE "WHATEVER". You were “expecting.”, Invented without a citation[
BUT AND A BIG BUT. Although 10% of sentences on the Net begin with conjunctions, Starting virtually every sentence with a conjunction would, of course, make your writing thoroughly monotonous.
NOT A SINGLE cannabis plant in any of the pictures. So what, read the story. Every true written word doesn’t contain pictures so widdle boys can understand them. Those are called comic books. Invented without a citation
I can’t go any further. This is clearly the most monotonous written, poorly grammatically written post ever. Grade, D-
Another "Big Bad Actor" Maneuver.
Did not care to double check this POS Private Co.
Now it turns out to be SUB-Saharan HIGH TECH MJ/CBD.
LONG CVSI
Actually I saw it, once. I prefer The Mission, Buena Vista Park or my Apt Bldg @ 820 Ashbury in the Haight. Fisherman’s Wharf is for tourists.
Marty,
Take a trip with me to Argentina, Chile, Colombia and then the DRC. Until you’ve been there and seen it with your own 2 eyes you can’t say with any degree of certainty in several years from now CVSI will be number 1.
You’re about to lift off, all the way to the greys.
Not yet.
But we are sourcing fom Colombia, Argentina and Chile.
We have planted Hemp and will be extracting soon. I’ve seen it with my own eyes. The costs are virtually nothing. Our largsest costs will be shipping.
No uplist for CVSI stock ever!